Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 2/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.58 |
| ▸ | ALPG | P10696 | 13/20 | 0.56 |
| ▸ | ALPL | P05186 | 10/20 | 0.56 |
| ▸ | PLAA | Q9Y263 | 8/20 | 0.55 |
| ▸ | ALPI | P09923 | 4/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | GFER | P55789 | 1/20 | 0.47 |
| ▸ | NSD2 | O96028 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22763954 | 0.84 | SMN1; SMN2 (0.52) | RAB9ASMN1; SMN2ALPGALPLPLAA | |
| SCHEMBL18825258 | 0.78 | SMN1; SMN2 (0.63) | RAB9ASMN1; SMN2GAAKDM4EGFER | |
| SCHEMBL18825265 | 0.76 | SMN1; SMN2 (0.66) | RAB9ASMN1; SMN2TSHR | |
| SCHEMBL18825263 | 0.76 | RAB9A (0.66) | RAB9ASMN1; SMN2TSHRKDM4E | |
| SCHEMBL18825267 | 0.75 | SMN1; SMN2 (0.81) | RAB9ASMN1; SMN2TDP1L3MBTL1TSHR | |
| SCHEMBL18825271 | 0.74 | TSHR (0.60) | RAB9ASMN1; SMN2TDP1L3MBTL1TSHR | |
| Bromide SCHEMBL6010245 | 0.73 | ALPG (0.56) | ALPGALPLPLAAALPITDP1 | |
| SCHEMBL5846697 | 0.73 | SMN1; SMN2 (0.77) | RAB9ASMN1; SMN2L3MBTL1TSHRKDM4E | |
| SCHEMBL12640291 | 0.72 | RAB9A (0.60) | RAB9ASMN1; SMN2L3MBTL1TSHRKDM4E | |
| SCHEMBL18825272 | 0.72 | NPC1 (0.64) | RAB9ASMN1; SMN2GAAKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11053227-B2 | Process for preparing intermediates for the synthesis of optically active beta-amino alcohols by enzymatic reduction and novel synthesis intermediates | OLON S.P.A. (IT) | 2021-07-06 | — | — | US | disclosed |
| US-20200385366-A1 | PROCESS FOR PREPARING INTERMEDIATES FOR THE SYNTHESIS OF OPTICALLY ACTIVE BETA-AMINO ALCOHOLS BY ENZYMATIC REDUCTION AND NOVEL SYNTHESIS INTERMEDIATES | OLON S.P.A. (IT) | 2020-12-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200385366-A1 | PROCESS FOR PREPARING INTERMEDIATES FOR THE SYNTHESIS OF OPTICALLY ACTIVE BETA-AMINO ALCOHOLS BY ENZYMATIC REDUCTION AND NOVEL SYNTHESIS INTERMEDIATES | ADH1A, ADH1C, ADH5 | RAB9A 3913/4885SMN1; SMN2 3396/4885ALPG 3780/4885 |
| US-11053227-B2 | Process for preparing intermediates for the synthesis of optically active beta-amino alcohols by enzymatic reduction and novel synthesis intermediates | ADH1A, ADH1C, ADH5 | RAB9A 3913/4885SMN1; SMN2 3396/4885ALPG 3780/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.